Literature DB >> 17655343

Subcellular proteome analysis of camptothecin analogue NSC606985-treated acute myeloid leukemic cells.

Yun Yu1, Li-Shun Wang, Shao-Ming Shen, Li Xia, Lei Zhang, Yuan-Shan Zhu, Guo-Qiang Chen.   

Abstract

We reported previously that NSC606985, a camptothecin analogue, induces apoptosis of acute myeloid leukemia (AML) cells through proteolytic activation of protein kinase Cdelta. Here, we analyzed protein expression profiles of fractionated nuclei, mitochondria, raw endoplasmic reticula, and cytosols of NSC606985-induced apoptotic AML cell line NB4 cells by two-dimensional electrophoresis combined with MALDI-TOF/TOF tandem mass spectrometry. In total, 90 unique deregulated proteins, including 16 compartment-compartment translocated ones, were identified. They contributed to multiple functional activities such as DNA damage repairing, chromosome assembly, mRNA processing, biosynthesis, modification, and degradation of proteins. More interestingly, several increased oxidative stress-related proteins mainly presented in mitochondria, while upregulated glycolysis proteins mainly occurred in the nuclei. With their functional analyses, the possible roles of these deregulated proteins in NSC606985-induced apoptosis were discussed. Collectively, these discoveries would shed new insights for systematically understanding the mechanisms of the camptothecin-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17655343     DOI: 10.1021/pr0700100

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  9 in total

Review 1.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.

Authors:  Bingnan Han; Luke H Stockwin; Chad Hancock; Sherry X Yu; Melinda G Hollingshead; Dianne L Newton
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

3.  Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells.

Authors:  Meng Zhao; Xu-Fang Duan; Xu-Yun Zhao; Bo Zhang; Ying Lu; Wei Liu; Jin-Ke Cheng; Guo-Qiang Chen
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

4.  Proteomic analysis of enriched lysosomes at early phase of camptothecin-induced apoptosis in human U-937 cells.

Authors:  Nicolas Parent; Eric Winstall; Myriam Beauchemin; Claudie Paquet; Guy G Poirier; Richard Bertrand
Journal:  J Proteomics       Date:  2009-04-23       Impact factor: 4.044

5.  Comparative mitochondrial proteomic analysis of Rji cells exposed to adriamycin.

Authors:  Yu-Jie Jiang; Qing Sun; Xiao-Sheng Fang; Xin Wang
Journal:  Mol Med       Date:  2009-02-05       Impact factor: 6.354

Review 6.  Comparative mitochondrial proteomics: perspective in human diseases.

Authors:  Yujie Jiang; Xin Wang
Journal:  J Hematol Oncol       Date:  2012-03-18       Impact factor: 17.388

7.  Microtubule-associated protein 1 light chain 3 interacts with and contributes to growth inhibiting effect of PML.

Authors:  Wei He; Chuan-Xi Hu; Jia-Kai Hou; Li Fan; Yi-Wei Xu; Man-Hua Liu; Shu-Yang Yan; Guo-Qiang Chen; Ying Huang
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

8.  KEGG spider: interpretation of genomics data in the context of the global gene metabolic network.

Authors:  Alexey V Antonov; Sabine Dietmann; Hans W Mewes
Journal:  Genome Biol       Date:  2008-12-18       Impact factor: 13.583

9.  AIF inhibits tumor metastasis by protecting PTEN from oxidation.

Authors:  Shao-Ming Shen; Meng Guo; Zhong Xiong; Yun Yu; Xu-Yun Zhao; Fei-Fei Zhang; Guo-Qiang Chen
Journal:  EMBO Rep       Date:  2015-09-28       Impact factor: 8.807

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.